Navigation Links
Clinical Trial Establishes Catheter-Based Aortic Valve Replacement as New Standard of Care for Patients Who Cannot Undergo Surgery
Date:9/22/2010

standard therapy). Among survivors at one year, the rate of cardiac symptoms was significantly lower among patients who had undergone TAVI, as compared with those who had received standard therapy (25.2 percent vs. 58.0 percent).

"Based on the reduction in mortality during the first year of the study, balloon-expandable TAVI should be the new standard of care in patients who are not suitable candidates for surgery," said Martin B. Leon, M.D., professor of medicine and director of the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital and Columbia University Medical Center. Dr. Leon, founder and chairman emeritus of the Cardiovascular Research Foundation, is the co-principal investigator of the study.

At 30 days, TAVI, as compared with standard therapy, was associated with a higher incidence of major strokes (5.0 percent vs. 1.1 percent) and major vascular complications (16.2 percent vs. 1.1 percent). In the year after TAVI, patients had no deterioration in the functioning of the bioprosthetic valve, as assessed by evidence of stenosis or regurgitation on an echocardiogram.

"This study shows that transcatheter valve replacement is a safe and effective option for this life-threatening illness in patients unsuitable for surgical valve replacement," said Dr. Smith, study co-principal investigator and surgeon-in-chief at NewYork-Presbyterian Hospital/Columbia University Medical Center. Dr. Smith is also the Valentine Mott Professor of Surgery, the Johnson & Johnson Distinguished Professor of Surgery, and chair of the Department of Surgery at Columbia University College of Physicians and Surgeons. "Additional studies are needed to examine the increased incidence of stroke following TAVI."

According to the study authors, research is already under way on the next generation of TAVI devices that researchers hope will address the vascular complications encountered in the trial.

Treatment of Aortic Steno
'/>"/>

SOURCE NewYork-Presbyterian Hospital/Columbia University Medical Center
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
10. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... NEW YORK , May 6, 2015  The ... ("GEVA" or the "Company") by Alexion Pharmaceuticals, Inc. ("Alexion") ... action, shareholder rights law firm, for possible breaches of ... Board of Directors of GEVA for agreeing to sell ... Company announced a definitive agreement for Alexion to acquire ...
(Date:5/6/2015)... Inc. (NASDAQ: SQNM ), a life sciences company committed ... and services, today reported total revenues of $37.8 million for ... to revenues of $37.1 million for the first quarter of ... $0.12 per share, basic and $0.11 per share, diluted, for ... $15.7 million, or $0.13 per share, basic and diluted, for ...
(Date:5/6/2015)... Inc. (Vanda) (NASDAQ: VNDA ), today announced financial ... 31, 2015. "The first quarter of 2015 ... HETLIOZ and Fanapt.  As we are just at the ... U.S., the growth potential for HETLIOZ remains ahead.  Similarly, ... potential of this product through the coming decade and ...
Breaking Medicine Technology:WeissLaw LLP Investigates the Synageva Biopharma Corp. Acquisition 2Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 2Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 3Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 4Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 5Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 6Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 7Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 8Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 9Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 10Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 11Sequenom, Inc. Reports Financial Results For The First Quarter Of 2015 12Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 9Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 10Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 11Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 12
... Group Inc. (Nasdaq: WWIN ) ("Winner Medical" or ... medical dressings and consumer products made from 100% cotton, today ... September 30, 2011. Fiscal ... 30.3% to $149.9 million from $115.0 million in the prior ...
... 2011  Watson Pharmaceuticals, Inc. (NYSE: WPI ) ... authorized generic version of LIPITOR® (atorvastatin calcium ... Inc.  Watson began shipping the product today.  LIPITOR® ... reduce elevated total cholesterol, LDL, triglycerides and to increase ...
Cached Medicine Technology:Winner Medical Reports Full Fiscal Year 2011 Results 2Winner Medical Reports Full Fiscal Year 2011 Results 3Winner Medical Reports Full Fiscal Year 2011 Results 4Winner Medical Reports Full Fiscal Year 2011 Results 5Winner Medical Reports Full Fiscal Year 2011 Results 6Winner Medical Reports Full Fiscal Year 2011 Results 7Winner Medical Reports Full Fiscal Year 2011 Results 8Winner Medical Reports Full Fiscal Year 2011 Results 9Winner Medical Reports Full Fiscal Year 2011 Results 10Winner Medical Reports Full Fiscal Year 2011 Results 11Winner Medical Reports Full Fiscal Year 2011 Results 12Winner Medical Reports Full Fiscal Year 2011 Results 13Winner Medical Reports Full Fiscal Year 2011 Results 14Winner Medical Reports Full Fiscal Year 2011 Results 15Winner Medical Reports Full Fiscal Year 2011 Results 16Winner Medical Reports Full Fiscal Year 2011 Results 17Watson Launches Generic LIPITOR® 2Watson Launches Generic LIPITOR® 3
(Date:5/6/2015)... FL (PRWEB) May 06, 2015 Qushanna Doby ... outside a nearby drug treatment center in Florida while under ... on May 4th. New surveillance tapes released by CBS4’s Peter ... without her baby. Doby’s child is around one year old. ... crying and shivering outside was not named. The residents polled ...
(Date:5/6/2015)... 05, 2014 (PRWEB) May 06, 2015 ... accepted, on behalf of MEBC, an Alliance Award ... JDA Software during FOCUS 2015, JDA’s annual user ... the manufacturing, retail and wholesale distribution sectors. This ... their clients are receiving services that advance their ...
(Date:5/6/2015)... Baltimore, MD (PRWEB) May 06, 2015 The ... Baltimore Ravens for the 6th annual charity softball ... 7:00pm at M & T Bank Stadium. Past years guests ... among others. Tickets are still on sale if ... been advocating for local non-profit organizations, such as SOAR ...
(Date:5/6/2015)... Jacksonville, Fla. (PRWEB) May 06, 2015 ... Orthopaedic Institute are the first in north Florida ... This technology is the latest innovation in total ... a highly advanced, surgeon-controlled robotic arm that enables ... Baptist Medical Center Jacksonville has offered MAKOplasty® partial ...
(Date:5/6/2015)... of Prussia, PA (PRWEB) May 06, 2015 ... Process Outsourcing solutions to the Medicare Advantage, Medicare Part ... finalists in the Continuity and Resilience Team category at ... the Business Continuity Institute to recognize the outstanding contribution ... operating in the North America Region, including the USA ...
Breaking Medicine News(10 mins):Health News:Flakka Induced Mother Abandons Baby, found by Florida Drug Treatment Center; New Video Released 2Health News:MEBC Receives Award for Consulting Excellence in Retail 2Health News:The Canton Group Sponsors Ravens Charity Softball Event 2Health News:The Canton Group Sponsors Ravens Charity Softball Event 3Health News:Baptist Health and Jacksonville Orthopaedic Institute Offering MAKOplasty® Total Hip Replacement 2Health News:Baptist Health and Jacksonville Orthopaedic Institute Offering MAKOplasty® Total Hip Replacement 3Health News:Baptist Health and Jacksonville Orthopaedic Institute Offering MAKOplasty® Total Hip Replacement 4Health News:TMG Health Recognized by the Business Continuity Institute 2Health News:TMG Health Recognized by the Business Continuity Institute 3
... PITTSBURGH , Feb. 12 Pittsburgh ... free antibiotics program in September of 2009, and is pleased ... $3 million in free prescriptions for customers in ... 590,000 prescriptions for free antibiotics have been filled by the ...
... , World-Renowned Policy Experts Held International ... , Global Town Hall Discussed How to Feed ... , WASHINGTON , Feb. 12 ... blizzard today to identify solutions for the greatest agricultural challenges of ...
... NEW YORK , Feb. 12 Dr. Jennifer Muller ... as the 2009 Veterinarian of the Year by Summit VetPharm® at the ... Show Dogs of the Year ® Awards, presented by Dogs In ... a leader in efforts to improve living conditions and strengthen regulations at ...
... , SHANGHAI , Feb. 12 ... of nutritional products, announced today that it, together with its parent ... strategic partnership with Bright Food (Group) Co., LTD (Bright Food). The ... ,s nutritional products market. Bright Food , a leading state-owned ...
... 12, 2010Hypnosis has potential therapeutic value in children with ... or unexplained sensations of difficulty breathing and for lessening ... hypnosis as an adjunct to conventional treatment and its ... physiological changes are explored in a provocative paper in ...
... than ,typical, flu season , FRIDAY, Feb. 12 (HealthDay News) ... federal health officials said Friday that about 57 million Americans ... total could range as high as 84 million. , In ... estimates that as many as 378,000 people were hospitalized due ...
Cached Medicine News:Health News:Giant Eagle Pharmacy Free Antibiotics Program Surpasses $3 Million in Free Prescriptions 2Health News:Now Serving 9 Billion: A Global Town Hall 2Health News:Now Serving 9 Billion: A Global Town Hall 3Health News:Now Serving 9 Billion: A Global Town Hall 4Health News:Dr. Jennifer Muller Named Veterinarian of the Year 2Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 2Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 3Health News:GNC Announces Entry to China's Nutritional Products in Partnership with Bright Food 4Health News:Hypnosis can relieve symptoms in children with respiratory diseases 2Health News:57 Million Americans Sickened by H1N1 Flu: CDC 2Health News:57 Million Americans Sickened by H1N1 Flu: CDC 3
... the "Consensus Concept" approach to design by ... of a Scientific Advisory Board. The result ... state-of-the-art features. Consensus Knee implants are designed ... and allow near normal kinematics. The components ...
The major innovations in posterior stabilized (PS) knee design....
The GENESIS II* Total Knee System will define the state of knee implants....
... system's curved-on-curved articulation maintains full inter-changeability. ... options for better patient fit. The ... spray porous coating, which offers an ... processed polyethylene is used for consistent, ...
Medicine Products: